IP Library Granted Patent US 9,204,996
Granted Patent B2
US 9,204,996 · App. 14/275,511 · Granted Dec 8, 2015

Presbyopia treatment by lens alteration

Inventors: Jonathan S. Till (Roanoke, VA); Ronald D. Blum (Roanoke, VA)
Assignee: Encore Health, LLC
A61F9/013A61F9/007A61F9/0017A61F9/0079A61K9/0048A61K38/063A61K38/45A61K41/00A61K41/0023A61K41/0042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,204,996
App. No.
14/275,511
Granted
Dec 8, 2015
Kind
B2
Abstract

This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.

Claims (15)

1. A method for reversing the effects of presybyopia comprising:

applying an external energy source to a lens of an eye; and administering a reducing agent to the lens to reduce the likelihood of reformation of lenticular disulfide bonds.

2. The method of claim 1 where the energy is of sufficient power to break lenticular disulfide bonds.

3. The method of claim 1 , wherein the energy is any form of electromagnetic radiation.

4. The method of claim 1 , wherein the energy is any form of sound energy.

5. The method of claim 1 , wherein the energy is any form of heat.

6. The method of claim 1 , wherein the reducing agent is glutathione, ascorbic acid, a thiol derivative, vitamin E, tetraethylthiuram disulfyl, ophthalmic acid, inositol, or a beta-carbolise.

7. The method of claim 1 , further comprising administering to the lens a methylating agent selected from the group consisting of methyl-methane thiosulfonate, methyl glutathione, S-methyl glutathione, S-transferase, and other biologically compatible methylating agents, wherein the reducing agent is capable of reducing the disulfide bonds into sulfhydryl groups; and wherein the methylating agent is capable of methylating the sulfhydryl groups.

8. The method of claim 7 , wherein the methylating agent comprises methyl-methane thiosulfonate.

9. The method of claim 7 , wherein the methylating agent comprises methyl glutathione.

10. The method of claim 7 , wherein the methylating agent comprises S-methyl glutathione.

11. The method of claim 7 , wherein the methylating agent comprises S-transferase.

12. The method of claim 1 , wherein the lens is a lens of a human eye.

13. The method of claim 1 , further comprising administering a catalyst to the lens.

14. The method of claim 13 , wherein the catalyst is selected from the group consisting of a reductase, an aldoreductase, a glyoxylase, a glutathione S-transferase, a thiol reductase, a tyrosine reductase, and a hexokinase.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2015
From: TILL, JONATHAN S.; BLUM, RONALD D.
To: NEWLENS, LLC
Reel/Frame 036545/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2015
From: TILL, JONATHAN S.
To: REFOCUS, LLC
Reel/Frame 036545/0168 →
CHANGE OF NAME Recorded Sep 11, 2015
From: NEWLENS, LLC
To: ENCORE HEALTH, LLC
Reel/Frame 036589/0967 →
CHANGE OF NAME Recorded Sep 11, 2015
From: REFOCUS, LLC
To: NEWLENS, LLC
Reel/Frame 036589/0976 →
Continuity (7)
Division 13028766 · Feb 16, 2011
Division 11010436 · Dec 14, 2004
Continuation 10050879 · Jan 18, 2002
Continuation In Part 09930287 · Aug 16, 2001
Provisional Application 60225659 · Aug 16, 2000
Provisional Application 60262423 · Jan 19, 2001
Related Publication 20140336562A1 · Nov 13, 2014